Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03445663 · ClinicalTrials.gov registry record · Phase 1
Study Evaluating AMG 424 in Subjects With Multiple Myeloma
A Phase 1 study, sponsored by Xencor.
- Terminated
- Registry status
- Phase 1
- Development phase
- 27
- Enrollment target
NCT03445663 is a Phase 1 study that was terminated before completion, run by Xencor. The registered enrollment target is 27 participants.
The verdict
NCT03445663, a Phase 1 study, was terminated before completion, sponsored by Xencor.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 27 participants
- Enrollment target
Study Summary
A multi-center Phase 1, First-in-Human study conducted in 2 Parts, testing AMG 424 in subjects with relapsed/ refractory multiple myeloma.
Interventions
- DRUG AMG 424
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 27 participants |
| Start Date | 2018-07-31 |
| Est. Completion | 2020-06-19 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03445663
The ClinicalTrials.gov registry entry for NCT03445663 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 27 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Xencor, which has 27 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which AMG 424 is the first listed.
NCT03445663 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03445663 about?
NCT03445663 is a clinical study titled "Study Evaluating AMG 424 in Subjects With Multiple Myeloma". A multi-center Phase 1, First-in-Human study conducted in 2 Parts, testing AMG 424 in subjects with relapsed/ refractory multiple myeloma.
What is the current status of trial NCT03445663?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 27 participants. The study started on 2018-07-31. Estimated completion is 2020-06-19.
What interventions are being tested in trial NCT03445663?
The interventions under investigation include: AMG 424 (DRUG).
Who is sponsoring clinical trial NCT03445663?
This trial is sponsored by Xencor, which has 27 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.